FDA 21 CFR 1271 Donor Eligibility and HCT/P Rules, Fertility Clinic Success Rate Act Outcome Reporting, CLIA Requirements for Andrology and Embryology Labs and Disposition Consent Records: Compliance for US Fertility Software

This article is part of our series on Custom Fertility and IVF Clinic Software Development for US Reproductive Medicine Practices: Building a Cycle Protocol, Witness and Cryostorage Chain-of-Custody System

Introduction: Tissue Regulation Meets Family Law

Fertility compliance sits at an intersection that has no real match anywhere else in healthcare. On one side sits federal tissue regulation, which treats reproductive cells as human tissue, carrying screening, testing, practice, and record obligations. On the other sits family law, because the material being regulated may one day become a child, and questions about who may use it, who counts as a parent, and what happens when people disagree get decided in state courts under law that differs considerably and continues to develop.

Between those two sits laboratory regulation governing the testing performed, plus a statutory outcome reporting obligation that exists partly because this field once had a genuine marketing problem. A platform here has to serve all four surfaces, and the consent records in particular have to survive long enough to be produced in circumstances nobody planned for at the time they were written.

This is educational content, not legal advice, and reproductive law in particular calls for specialist counsel rather than general guidance. For reproductive medicine platform development, custom software development has to model the consent and eligibility distinctions explicitly from day one, and web application development for the patient portal has to respect the same boundaries around what a system can and cannot communicate to a patient.

FDA 21 CFR 1271 Donor Eligibility and HCT/P Rules

Reproductive Cells Are Regulated Tissue

Federal regulation of human cells, tissues, and cellular and tissue-based products, codified at 21 CFR Part 1271 and effective since May 2005, covers reproductive material directly. The framework includes establishment registration and listing, donor eligibility determination where it applies, current good tissue practice covering facilities, equipment, processes and records, labeling, and record retention for defined periods. Verify current requirements and any recent rule changes directly with FDA guidance and counsel before finalizing any product scope.

The Partner Distinction Is Operationally Central

One distinction runs through the whole framework and drives a substantial amount of workflow on its own. The framework treats reproductive material from a sexually intimate partner differently from donor material more broadly, including directed and anonymous donors. This means a practice must establish which category applies for every single case and record that determination clearly and consistently. Verify the precise boundaries of this distinction with counsel rather than relying on any general description, since the exact scope and any exceptions are a matter for current regulatory guidance.

A platform that does not model this distinction explicitly will produce records that cannot demonstrate which rules were actually followed if the question ever arises later.

What the Platform Holds

The determination made for each case, with its basis, belongs in the record. Screening and testing results where eligibility determination applies, with the documentation supporting them. Labeling and identification consistent with regulatory requirements. Records retained for the applicable period. Adverse reaction reporting capability. And the deviations and investigations a good tissue practice framework expects to see documented as a matter of course. Confirm current requirements directly with FDA guidance and counsel.

Fertility Clinic Success Rate Act Outcome Reporting

An Obligation With a History Worth Knowing

This obligation has an origin worth understanding, because it explains why the framework treats the resulting data the way it does throughout.

The Fertility Clinic Success Rate Act requires practices performing assisted reproductive technology to report outcome data annually, with the data published so prospective patients can see it. The legislation followed a period in which success rate claims in advertising were inconsistent, incomparable, and in some cases genuinely misleading, and people were making enormously consequential decisions based on numbers that did not reflect reality.

Two Practical Consequences for a Platform

What gets reported is cycle level: the characteristics of the cycle, what was done, and what resulted, with definitions prescribed so figures mean the same thing across every reporting practice. That consistency is the entire point of the law.

Two practical consequences follow for anyone building software here. The cycle model needs to align with the reporting definitions from the very beginning, because reconciling a differently structured record every single year is both expensive and genuinely error-prone. And outcome completeness is a data collection problem more than a submission one. Pregnancy and birth outcomes occur after the patient has left the practice’s routine care, which means following up directly, and incomplete data is both a reporting failure and a distortion of the practice’s own understanding of its results.

The data is reported, not marketed. Verify current specifications directly with the reporting program.

CLIA Requirements for Andrology and Embryology Laboratories

A Clear Part and a More Nuanced Part

Laboratory regulation here has a clear part and a more nuanced part, and practices should establish their own position rather than assume it applies uniformly.

Andrology testing, semen analysis and related testing performed on patient specimens for diagnostic purposes, falls within the federal clinical laboratory framework, with obligations covering certification, personnel qualifications, proficiency testing, quality control, and quality assessment. Embryology’s position is more nuanced, since much of what an embryology laboratory does is procedure rather than diagnostic testing on specimens in the traditional sense. Practices should establish which of their activities fall within the framework by referring to current guidance rather than working from assumption.

Accreditation and What the Platform Holds

Accreditation programs operate in this field with their own standards for reproductive laboratories, addressing personnel, procedures, quality management, equipment, and records. Professional society membership commonly requires laboratory accreditation, which makes it effectively obligatory for many practices in practice, regardless of its formal legal status.

For the platform: personnel qualifications and competency assessments held with currency, quality control and proficiency records, equipment maintenance and calibration, procedure documentation, and the records an inspection examines available continuously rather than assembled under pressure when the moment arrives. Verify specific requirements with counsel and the relevant accrediting body directly.

Disposition Consent Records

Where a Software Obligation Becomes a Legal One

This is where a software requirement becomes a genuinely legal one, and where the consequences of getting it wrong reach the furthest.

When patients cryopreserve material, they execute directions covering circumstances that may arise later: death of one or both partners, divorce or separation, loss of contact, non-payment, or their own decision to stop storing altogether. Different practices use different frameworks, and the specific options offered to patients vary from clinic to clinic.

Three Things That Make This Genuinely Hard

Three things make this area especially difficult to get right in software.

The directions are executed at a moment when the people involved are aligned and hopeful, and they may be invoked years later when they no longer are. Disputes over stored embryos are genuinely litigated, and courts in different states have reached different conclusions, sometimes enforcing the consent as a binding contract, sometimes not, sometimes weighing the parties’ current positions against what they wrote years earlier.

The record itself must survive. A consent executed today may be needed in twenty years, after system migrations and possibly after the practice has changed ownership entirely.

And nothing may ever be inferred. A patient who cannot be reached has not consented to anything. Non-payment is a contractual matter with its own separate remedies, not an instruction about what happens to material.

For the platform: consents held as executed, by version, with each person’s agreement and date, retrievable long term, review cycles surfaced for staff to act on, contact attempts recorded, and no automated action on material under any circumstance. Obtain counsel experienced specifically in reproductive law before finalizing how any of this gets built.

State Law, Parentage, and Third-Party Reproduction

Where Variation Runs Deepest

Above the federal framework sits state law, and it varies more here than in almost any other area of healthcare.

Parentage law determines who is recognized as a legal parent of a child conceived using donated material or carried by a gestational carrier, and the answers differ between states, with some having comprehensive statutes and others very little guidance at all. Gestational carrier arrangements get treated very differently by state too: permitted and regulated in some, restricted or unenforceable in others, which directly affects whether and how a practice can participate.

A Changing Landscape

Donor anonymity is a genuinely changing landscape. Consumer genetic testing has made anonymity difficult to guarantee regardless of what was originally promised, and some jurisdictions have moved toward donor-identity disclosure at adulthood. Practices making representations to donors and recipients about anonymity should do so only with current advice, not assumptions carried over from years past.

Posthumous use of gametes and embryos raises its own set of questions with varying answers by state. And storage abandonment, what a practice may do with material whose owners cannot be reached, is governed by contract, consent, and state law together, and it is a situation that recurs more often than practices expect.

For the platform: record what was agreed and by whom. The legal determinations themselves belong with specialist counsel, not with a workflow design decision.

Other Obligations

A shorter list rounds out the compliance picture.

• Privacy and security requirements for a record that is unusually sensitive and unusually long-lived
• State facility licensure and physician licensure
• Advertising rules governing how services and outcomes may be presented to prospective patients
• Financial arrangements including refund and shared-risk programs, which carry consumer protection considerations in some states
• Shipping requirements for cryopreserved material, including international movement where it applies
• Genetic testing laboratory relationships and the consent covering that testing
• Medical device reporting where equipment may have contributed to an adverse event
• Employment and laboratory safety requirements, including liquid nitrogen handling, which carries genuine asphyxiation risk
• Insurance and employer benefit program terms where coverage applies
• Professional society standards, which function as binding requirements for member practices whatever their formal legal status

Final Thoughts

Practices that model the partner and donor distinction explicitly, align their cycle record with reporting definitions from the start, hold laboratory qualification and quality records continuously, and keep disposition consents as executed and retrievable for decades end up with a platform that can answer the questions that arrive years later, in circumstances nobody planned for at the outset.

This is educational content, not legal advice. Confirm the specifics with healthcare regulatory counsel, counsel experienced in reproductive law, and the accrediting body before treating anything here as final guidance. If you are scoping fertility software, checking how quickly you could produce the executed consent for material stored a decade ago is the question most likely to surface. Learn more about digital transformation solutions from one of the leading AI software companies in the United States.

FAQ